Svetlana Lucas

Chief Business Officer Svetlana Lucas purchased 3,000 shares at $15.00 in private placement allocation.

Svetlana Lucas, Chief Business Officer, acquired 3,000 shares at $15.00 on 2026-07-23, representing her initial equity stake in Scribe Therapeutics. This transaction is a private placement allocation, not a discretionary open-market purchase driven by insider conviction. Lucas maintains substantial derivative holdings totaling 228,399 shares across three stock option vehicles (9,547 shares and 109,426 shares in two separate option pools), indicating meaningful long-term incentive participation. The purchase occurred during SCTX's recent IPO window, consistent with early-stage allocation patterns rather than a signal of executive confidence in current valuation.

Director Lucas Svetlana buys 20,000 shares of JSPR at $2.43 amid 3-insider cluster; stock down 90.6% from 52-week high of $24.73

Lucas Svetlana, a director, purchased 20,000 shares at $2.43 on 2025-09-22, establishing a new position worth $48,600.00. This transaction is part of a cluster pattern with 3 other insiders buying within the past 14 days. The stock is trading at a severe discount to its 52-week high of $24.73 (currently $2.33, down 90.6%), having declined 59.0% over 90 days and 21.3% over 30 days. Jasper Therapeutics reported a net loss of $26.7M in its most recent fiscal year with a market cap of $37.9M, indicating material unprofitability. The convergence of multiple insider purchases at depressed valuations alongside pronounced losses and significant downward price momentum warrants close examination of the company's operational trajectory and near-term catalysts.